Heron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/01/22
Heron Therapeutics (HRTX) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/01/22
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate UpdatesPRNewsWire • 02/28/22
Heron Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022PRNewsWire • 02/22/22
Heron Therapeutics Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF®PRNewsWire • 12/09/21
Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDAPRNewsWire • 11/18/21
Heron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/04/21
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/03/21
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate UpdatesPRNewsWire • 11/03/21
Heron Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 3, 2021PRNewsWire • 10/28/21
Bluebird Bio or Heron Therapeutics: Which Stock Is the Better Comeback Play?The Motley Fool • 10/11/21
Heron Therapeutics Announces Filing of a Supplemental New Drug Application for Significant Expansion of ZYNRELEF® Indication Statement Based on Successful Outcome of FDA Type C MeetingPRNewsWire • 10/04/21
Heron Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare ConferencePRNewsWire • 09/21/21
Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/09/21
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent Corporate UpdatesPRNewsWire • 08/09/21